Dr. Martine Rothblatt founded Lung Biotechnology, as well as our parent company, United Therapeutics, in order to develop therapies for orphan diseases such as PAH.
She earned her PhD in medical ethics from the Royal London School of Medicine and Dentistry, Queen Mary College, University of London and also obtained JD and MBA degrees from the University of California at Los Angeles. Prior to entering the life sciences field, Dr. Rothblatt was active in satellite communications, founding Sirius XM Satellite Radio and serving as its Chairman and CEO. She has also published many books, including Your Life or Mine: How Geoethics Can Resolve the Conflict Between Public and Private Interests in Xenotransplantation.
Marc Lorber has been Chief Medical Officer and Senior Vice President, Clinical Development, XenoLung, since August 2012.
Prior to joining Lung Biotechnology, he served in several drug development roles at Novartis, most recently as Vice President and Therapeutic Area Head, responsible for transplantation, nephrology and autoimmunity indications in the IHC Global Development Franchise. Prior to joining Novartis in 2007, Dr. Lorber was Chief of Organ Transplantation and Immunology at Yale University School of Medicine for nearly 21 years, where he was also Professor of Surgery and Pathology. He was an active researcher and busy clinical transplant surgeon; he has published extensively and delivered scientific addresses in his areas of expertise throughout the world. Also notable, Dr. Lorber is Past President of the American Society of Transplant Surgeons, a past member of the Board of Directors and Secretary of the United Network for Organ Sharing, and he served on the Advisory Committee for Organ Transplantation, U.S. Department of Health and Human Services.
Aimee Smart is the Associate Vice President of Clinical Development & Regulatory Processes at Lung Biotechnology. Prior to this, she was Director of Regulatory Affairs for VIRxSYS Corporation and worked in regulatory affairs at Human Genome Sciences, Nabi Biopharmaceuticals, and Cato Research, where she held positions with increasing responsibility for US and international regulatory activities. Ms Smart brings with her several years of experience working in regulatory affairs along with a wealth of knowledge in creating and implementing strategies with the goal of successful US and international regulatory filings. In her current position, at Lung Biotechnology, Ms. Smart leads the Regulatory and Clinical R&D teams.
Thank you for visiting the Lung Biotechnology Website.
We have detected you are using an old browser. The website is best viewed in latest versions of internet browsers. You can download latest version of browser of choice here.